Ozmosi | Fedovapagon Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Fedovapagon

Alternative Names: fedovapagon, va-106483, va106483, va 106483
Clinical Status: Inactive
Latest Update: 2018-10-31
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: V2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vantia
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Nocturia|Prostatic Hyperplasia

Phase 2: Nocturia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT02537288

NCT02537288

P1

Completed

Nocturia

2015-12-01

2024-11-27

NCT02440841

NCT02440841

P1

Completed

Nocturia

2015-07-01

2019-03-20

Treatments

NCT01330927

NCT01330927

P1

Completed

Nocturia|Prostatic Hyperplasia

2011-07-01

2019-03-19

Treatments

NCT01171391

NCT01171391

P1

Completed

Nocturia

2010-11-01

2019-03-19

NCT00922740

NCT00922740

P1

Completed

Nocturia

2009-07-01

2019-03-18

Treatments

NCT00879216

NCT00879216

P1

Completed

Nocturia

2009-05-01

2019-03-18

Treatments

NCT01656239

NCT01656239

P2

Completed

Nocturia

2013-08-01

2019-03-19

Treatments

NCT01038843

NCT01038843

P2

Completed

Nocturia

2010-07-01

2019-03-19

Treatments

2008-003774-17

2008-003774-17

P2

Completed

Nocturia

2009-02-02

2022-03-12

Treatments

NCT00879138

NCT00879138

P2

Completed

Nocturia

2009-02-01

2019-03-18

Treatments

NCT02637960

EQUINOC

P3

Completed

Nocturia|Prostatic Hyperplasia

2017-07-01

2019-03-20

Recent News Events

Date

Type

Title